314 related articles for article (PubMed ID: 9749589)
1. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
Shoulson I
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
[TBL] [Abstract][Full Text] [Related]
2. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
[TBL] [Abstract][Full Text] [Related]
3. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
Ann Neurol; 1996 Jan; 39(1):29-36. PubMed ID: 8572663
[TBL] [Abstract][Full Text] [Related]
4. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
LeWitt PA
J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399
[TBL] [Abstract][Full Text] [Related]
6. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
7. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection in Parkinson's disease: clinical trials.
Stocchi F; Olanow CW
Ann Neurol; 2003; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
[TBL] [Abstract][Full Text] [Related]
9. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
Schneider E
J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
[TBL] [Abstract][Full Text] [Related]
10. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group.
Shoulson I
Acta Neurol Scand Suppl; 1989; 126():171-5. PubMed ID: 2515723
[TBL] [Abstract][Full Text] [Related]
11. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Shoulson I
Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
[TBL] [Abstract][Full Text] [Related]
12. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
Marras C; Lang AE; Eberly SW; Oakes D; Fahn S; Schwid SR; Hyson C; Shoulson I;
Mov Disord; 2009 Dec; 24(16):2370-8. PubMed ID: 19908310
[TBL] [Abstract][Full Text] [Related]
13. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
Parkinson Study Group
N Engl J Med; 1993 Jan; 328(3):176-83. PubMed ID: 8417384
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
Tilley BC; Palesch YY; Kieburtz K; Ravina B; Huang P; Elm JJ; Shannon K; Wooten GF; Tanner CM; Goetz GC;
Neurology; 2006 Mar; 66(5):628-33. PubMed ID: 16534099
[TBL] [Abstract][Full Text] [Related]
15. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
16. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
Clarke CE
Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
18. Moderate Parkinson's disease. Strategies for maximizing treatment.
Silverstein PM
Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Olanow CW; Jankovic J
Mov Disord; 2005; 20 Suppl 11():S3-10. PubMed ID: 15822111
[TBL] [Abstract][Full Text] [Related]
20. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
Marras C; McDermott MP; Rochon PA; Tanner CM; Naglie G; Rudolph A; Lang AE;
Neurology; 2005 Jan; 64(1):87-93. PubMed ID: 15642909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
